To be effective when taken orally, IgY antibodies must withstand the harsh environment of the digestive system. Protecting them from gastric degradation is essential for consistent immune benefits.

The Challenge

• In ex vivo studies, IgY lost over 5–8 log₂ antibody titers within 30–60 minutes of exposure to chicken stomach content.
  View study on PubMed
• In static in vitro digestion models, IgY showed low digestibility (~24%), indicating partial resistance but limited bioavailability.
  Details via PubMed Central

Innovative Solutions

• Microencapsulation using biopolymers like alginate-chitosan enhances IgY’s stability and targeted release in the intestine.
• Polymer coatings have proven to protect IgY against acidic pH and enzymatic breakdown in the stomach.
  Read more

ActiveImmunity integrates these findings into its proprietary low-temperature process and delivery forms. The result: stable, functional, and targeted IgY antibodies that maintain efficacy where it matters most — inside the body.